3,4-dihydroxyphenylacetaldehyde has been researched along with Parkinsonian Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooney, A; Goldstein, DS; Gross, DJ; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P; Sullivan, R | 1 |
1 other study(ies) available for 3,4-dihydroxyphenylacetaldehyde and Parkinsonian Disorders
| Article | Year |
|---|---|
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoplasmic Vesicles; Dopamine; Neurons; Parkinsonian Disorders; PC12 Cells; Rats | 2012 |